Brain tumor
Glioblastoma multiforme (GBM) is the most aggressive (grade IV) and most common form of a malignant brain tumor. Even when aggressive multimodality therapy consisting of radiotherapy, chemotherapy, and surgical excision is used, median survival is only 12–17 months. Standard therapy for glioblastoma multiforme consists of maximal surgical resection of the tumor, followed by radiotherapy between two and four weeks after the surgical procedure to remove the cancer, then by chemotherapy, such as temozolomide. Most patients with glioblastoma take a corticosteroid, typically dexamethasone, during their illness to relieve symptoms. Experimental treatments include targeted therapy, gamma knife radiosurgery, boron neutron capture therapy and gene therapy.
Hypodiploid acute lymphoblastic leukemia
Hypodiploid acute lymphoblastic leukemia is the chromosome mutation of leukemic cells with 45 chromosomes or less. It has been determined that the prognosis of hypodiploid is much less than standard acute lymphoblastic leukemia. The lower the chromosome count, the lower the survival rate. In a study documented by the American Society of Hematology 17 of 27 patients relapsed, which indicates poor treatment responsiveness of hypodiploid ALL.
Hypodiploid is an unfavorable karyotypic feature in childhood ALL.